How can ALL people (consumers) have a voice in PBAC and MSAC processes?
In this webinar, hear from Dr John Rule (NAPWHA Senior Research Manager) on the importance of Patient-based Evidence: Using qualitative research.
“[People living with HIV have historically] been pairing people up to help another person develop their health literacy. We are playing with a similar concept in terms of our engagement in research. We [communities of consumers] need to develop a research literacy ourselves, and we do have to learn about how the science operates, and the role of qualitative research in sometimes countering what science might assume, but also adding to science.”
In a 3-part webinar series, the Patient Voice Initiative invited various patient groups and communities wanting to know about qualitative research for reimbursement decisions in Australia. This included NAPWHA, who participates sporadically in consumer hearings to the Pharmaceutical Benefits Advisory Committee (PBAC) to better inform them of key issues and evidence from people living with HIV.
Watch the video
The webinar (above) from Friday 21 August 2020 focused on answering questions about qualitative research for submissions to the Pharmaceutical Benefits Advisory Committee (PBAC) and Medical Services Advisory Committee (MSAC).
In this video, hear from:
- Dr Stephen Holden (Adjunct Professor, Macquarie Graduate School of Management) speaking on What is qualitative research and what can it do?
- Dr John Rule (NAPWHA Senior Research Manager) speaking on Patient-based Evidence: Using qualitative research [download the presentation slides PDF]
Patients want to be involved. Patients need to be involved, and patients are more informed now than they have ever been.
Never has there been a more important time than now to have a more inclusive and consultative environment to ensure that the people of Australia are cared for, listened to and part of the conversation.
– Kathy Gardiner (metastatic melanoma patient)
What is the Pharmaceutical Benefits Advisory Committee (PBAC)
Because the amount of taxpayer funding available for medicines is limited, to be listed on the PBS, a medicine must be assessed as being good value for money. This assessment, known as a health technology assessment, is done by the Pharmaceutical Benefits Advisory Committee (PBAC) who are an advisory committee of the Australian Government that primarily makes recommendations to the health minister.
What does the health technology assessment (HBA) do?
To assess whether a medicine is safe, clinically effective, and cost-effective compared to an existing treatment, PBAC uses a process called health technology assessment. This is a type of policy research used in more than 30 countries to assess the value of a medicine using recognised scientific processes and robust evidence. PBAC assessments take 17 weeks.
What you pay for PBS medicines
To help meet the cost of the scheme, you pay a proportion (a ‘co-payment’) for your PBS medicines and the Government pays the rest of the cost. The Australian Government subsidises medicines that are necessary to maintain the health of the community in a way that is cost effective. Community need and/or benefit are also considered.
How does PBAC work
The Pharmaceutical Benefits Advisory Committee is made up of doctors, health professionals, health economists and two consumer representatives; Jo Watson and Bel Harper. Jo is also Deputy Chair, with Professor Andrew Wilson as the Chair.
What is the Medical Services Advisory Committee (MSAC)
The Medical Services Advisory Committee (MSAC) is an independent committee established by the Australian Government Minister for Health who appraises new medical services proposed for public funding.
It provides advice to Government on whether a new medical service should be publicly funded (and if so, its circumstances) on an assessment of its comparative safety, clinical effectiveness,cost-effectiveness, and total cost, using the best available evidence. Amendments and reviews of existing services funded on the Medical Benefits Schedule (MBS) or other programmes (for example, blood products or screening programmes) are also considered by MSAC.